Hot Topics for Food, Drug and Cosmetic Law Section
Brian J. Malkin, Chair of the NYSBA Food, Drug and Cosmetic Law Section writes: The Food, Drug and Cosmetic Law Section this year has focused its program in selecting topics of a cross-functional nature, as discussed below.
January 19, 2018 at 02:00 PM
3 minute read
The Food, Drug and Cosmetic Law Section this year has focused its program in selecting topics of a cross-functional nature, as discussed below.
Tobacco Product Law
First, a panel will address a new initiative undertaken by the U.S. Food and Drug Administration (FDA) to reduce the highly-addictive drug, nicotine, found in most tobacco products. Next, the panel will consider how the Center for Tobacco Products (CTP) utilizes a substantial equivalence process for certain tobacco products that shares many similarities with substantial equivalence used for 510(k)-type medical devices, as well as another look at tobacco flavors.
Animal Health Law
The Animal Health Law Panel then plans to discuss leveraging approved human drugs in the process to obtain animal drug approvals and features speakers from animal health companies offering their perspectives on key features in the animal drug regulatory approval process and business considerations affecting the process.
Food Law
Next, the Food Law panel features speakers discussing issues related to genetically-modified organisms (GMOs) that result in food and animal products tied to how the FDA and the U.S. Department of Agriculture (USDA) regulates those products. The science that brings us to GMOs are genes and biologic manipulation, which shares some technologic features to gene-based therapies that will be discussed in the biologics and medical device panels.
Biologics Law
The Section's Biologics panel features discussions on FDA's approval of the first gene therapies, intellectual property considerations for patenting such therapies, and an update on biosimilar market entrants, and how the Supreme Court decision on the biosimilar litigation process has raised strategy questions for prospective biosimilar applicants. This panel features speakers from both FDA's Center for Biologics Evaluation and Research and the New York Genome Center.
Ethics
An ethics panel designed for attorneys involving early access promises to provide many insights into how human subjects can be protected and potentially benefit when using unapproved medical therapies, which has been a hot topic, where increased drug access has been emphasized.
Drug Law
Following ethics, a drug law panel with the New York Attorney General's Health Care Bureau Chief will discuss how New York is addressing the opioid drug crisis, and then will include a lively debate between a distinguished academic and former Assistant Director of the U.S. Federal Trade Commission (FTC) (now litigator), considering how generic competition may be encouraged by additional FDA/FTC statutory or regulatory measures. This panel also includes a discussion of a new tactic to avoid potentially certain pharmaceutical patent challenges involving patent ownership by Indian tribes or state entities and the invocation of sovereign immunity.
Medical Device Law
The program concludes with a medical device panel focusing on device and software regulation following the 21st Century Cures Act, safety, privacy and data/cyber-security in an era of digital devices, and FDA's evolving policy on personalized medicine, featuring a discussion on gene-based tests.
Brian J. Malkin is counsel at Arent Fox.
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Trending Stories
- 1What We Know About the Kentucky Judge Killed in His Chambers
- 2Judge Blasts Authors' Lawyers in Key AI Suit, Says Case Doomed Without Upgraded Team
- 3Federal Judge Won't Stop Title IX Investigation Into Former GMU Law Professor
- 4'I'm Staying Everything': Texas Bankruptcy Judge Halts Talc Trials Against J&J
- 5NY Judge Resigns Amid Investigation of Alleged Unwelcome Sexual Advances, Judgments for Friends
Who Got The Work
Charles A. Weiss of Holland & Knight has entered an appearance for Rafael Badalov in a pending trademark infringement lawsuit. The suit, filed July 26 in New York Eastern District Court by Lee Law on behalf of Otter Products LLC, accuses the defendant of selling counterfeit phone cases and accessories bearing the plaintiff's 'OtterBox' trademark. The case, assigned to U.S. District Judge Nina R. Morrison, is 1:24-cv-05214, Otter Products, LLC v. Badalov et al.
Who Got The Work
Gibson, Dunn & Crutcher partners Benjamin Hershkowitz, Richard W. Mark and Casey J. McCracken and R. Scott Johnson, Thomas M. Patton and Cara S. Donels have entered appearances for Berkshire Hathaway Energy Co. and MidAmerican Energy Co., respectively, in a pending patent infringement lawsuit. The case, filed July 17 in Iowa Southern District Court by Nyemaster Goode PC and Caldwell Cassady & Curry on behalf of Midwest Energy Emissions Corp., asserts six patents related to sorbents for the oxidation and removal of mercury. The case, assigned to U.S. District Judge Stephen H. Locher, is 4:24-cv-00243, Midwest Energy Emissions Corp. v. Berkshire Hathaway Energy Company et al.
Who Got The Work
Michael J. Hickey and Michael L. Jente of Lewis Rice LLC have stepped in to represent Tidal Wave Management in a pending trademark infringement lawsuit. The case, filed July 18 in Missouri Western District Court by Husch Blackwell on behalf of Waterway Gas & Wash Co., accuses the defendant of using a mark that's confusingly similar to the plaintiff's 'Clean Car Club' mark. The case, assigned to U.S. District Judge Fernando J. Gaitan Jr., is 4:24-cv-00471, Waterway Gas & Wash Company v. Tidal Wave Management LLC.
Who Got The Work
Wachtell, Lipton, Rosen & Katz partners Lauren M. Kofke and William Savitt have stepped in to represent CVS Health and and its top officials in a pending shareholder derivative lawsuit. The complaint, filed Aug. 30 in New York Southern District Court by the Brown Law Firm on behalf of Chaya Sara Kaufmann, accuses the defendants of failing to disclose that they used misleading forecasts to set premium plans which overstated the profitability of the company's health care benefits segment. The case, assigned to U.S. District Judge Margaret M. Garnett, is 1:24-cv-06595, Kaufmann v. Lynch et al.
Who Got The Work
Robert L. Wallan from Pillsbury Winthrop Shaw Pittman has entered an appearance for Findlay Management Group in a pending complaint for declaratory judgment. The complaint, filed on Aug. 8 in Nevada District Court by Gordon Rees Scully Mansukhani and Skarzynski Marick & Black on behalf of Houston Casualty Co., seeks to declare that no insurance policy exists between Houston Casualty and Findlay due to there not being an adequate form of delivery and claims that if delivery was substantiated it is rescinded based on material omissions and misrepresentations. The case, assigned to U.S. District Judge Gloria M. Navarro, is 2:24-cv-01459, Houston Casualty Company v. Findlay Management Group.
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250